logo

For the Inventor, By the Inventor

Ghent, Belgium

Argenx Bv

Calculating rank
USPTO Granted Patents = 31



Trademarks = 10

Forward Citations = 95

Loading Chart...
Loading Chart...

59 inventors (with patents filed for the assignee):

goldMedal Christophe Blanchetot (12 out of 25 patents)

silverMedal Johannes Joseph Wilhelmus De Haard (12 out of 34 patents)

bronzeMedal Torsten Dreier (11 out of 27 patents)

4.  Christophe Frederic Jerome Blanchetot (7 out of 12 patents)

5.  Karen Silence (6 out of 25 patents)

6.  Johannes De Haard (6 out of 13 patents)

7.  Peter Ulrichts (5 out of 10 patents)

8.  Sebastian Paul Van Der Woning (5 out of 14 patents)

9.  Michael Saunders (4 out of 13 patents)

10.  Mahan Moshir (4 out of 7 patents)

11.  Hans De Haard (3 out of 20 patents)

12.  Luc Van Rompaey (3 out of 3 patents)

13.  Judith Baumeister (3 out of 3 patents)

14.  Jolien Van Santbergen (3 out of 3 patents)

15.  Vladimir Bobkov (3 out of 3 patents)


Core Competencies:
FcRn
Antibody
Bispecific
Pemphigus
IL-5
IL-4R
C2B
Combination Therapy
Antigen Binding
Humanized Antibodies
Galectin-10
Myasthenia Gravis

31 patents:

1. 12774348 - FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USE (2026-10-27),
2. 12708664 - METHODS OF TREATING PARAPROTEINEMIC NEUROPATHY WITH ANTI-C2 ANTIBODIES (2026-08-18),
3. 12565538 - FCRN/ANTIGEN-BINDING MOLECULES AND METHODS OF USE (2026-03-03),
4. 12403175 - Methods for treating pemphigus disorders (2025-09-02),
5. 12344678 - FcRn/HSA binding molecules and methods of use (2025-07-01),
6. 12240875 - Use of FCRN antagonists for treatment of generalized myasthenia gravis (2025-03-04),
7. 12202900 - Compositions and methods for treating immune thrombocytopenia (2025-01-21),
8. 12180293 - CD70 combination therapy (2024-12-31),
9. 12071486 - Bispecific antigen binding construct (2024-08-27),
10. 12060413 - Method of preparing pH-dependent antibodies (2024-08-13),
11. 12030949 - Multispecific antibodies against IL-5 and IL-4R (2024-07-09),
12. 11827701 - IL-6 binding molecules (2023-11-28),
13. 11713354 - Galectin-10 antibodies (2023-08-01),
14. 11712468 - CD70 combination therapy (2023-08-01),
15. 11708403 - Antibodies to human complement factor C2B and methods of use (2023-07-25),
Company Overview
Argenx Bv is a biotechnology company based in Ghent, Belgium, specializing in the development of innovative therapies for the treatment of severe autoimmune diseases and cancer. The company focuses on harnessing its proprietary antibody engineering platform to create novel therapeutic antibodies that target specific disease mechanisms. With a commitment to advancing patient care, Argenx collaborates with various stakeholders in the healthcare ecosystem to bring transformative treatments to market.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 27 2026

31 Patents

#7 in Ghent

#114 in Belgium

#21,301 in the World

Ghent, BE
Ghent, Belgium

Argenx Bv

Forward Citations = 95

59 inventors:

goldMedal Christophe Blanchetot (12 out of 25 patents)

silverMedal Johannes Joseph Wilhelmus De Haard (12 out of 34 patents)

bronzeMedal Torsten Dreier (11 out of 27 patents)

4.  Christophe Frederic Jerome Blanchetot (7 out of 12 patents)

5.  Karen Silence (6 out of 25 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Argenx Bv. Retrieved from https://idiyas.com/company/argenx-bv

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…